Case number 1:23-cv-00448
AbbVie Inc. v. Hetero Labs Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Aug 16, 2023 | 13 | SO ORDERED Granting (D.I. 12 in 23-cv-374-RGA; D.I. 13 in 23-cv-607-RGA; D.I. 6 in 23-cv-750-RGA; D.I. 12 in 23-cv-448-RGA; D.I. 9 in 23-cv-684-RGA; D.I. 113 in 22-cv-1423-RGA-JLH; D.I. 13 in 23-cv-00470-RGA) Stipulation and Proposed Order Concerning Amended Complaint and Consolidation (see Order for further details). Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:22-cv-01423-RGA-JLH et al.(nms) (Entered: 08/16/2023) (7) |
| Aug 10, 2023 | 12 | STIPULATION and Proposed Order Concerning Amended Complaint and Consolidation, AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibits A-G, # 3 Supplemental ANDA form, # 4 Supplemental ANDA form, # 5 Supplemental ANDA form, # 6 Amended Patent Report, # 7 Exhibit 2)(Tigan, Jeremy) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (0) |
| Jul 24, 2023 | 11 | ANSWER to 8 Answer to Complaint and Counterclaim, by AbbVie Inc..(Tigan, Jeremy) Modified on 7/24/2023 (nms). (Entered: 07/24/2023) (10) |
| Jul 5, 2023 | 9 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Drugs Limited for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Grivner, Geoffrey) (Entered: 07/05/2023) (2) |
| Jul 5, 2023 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 07/05/2023) (0) |
| Jul 3, 2023 | 8 | ANSWER to 1 Complaint, , COUNTERCLAIM against AbbVie Inc. by Hetero Labs Limited Unit-V, Hetero USA Inc., Hetero Labs Limited.(Grivner, Geoffrey) (Entered: 07/03/2023) (25) |
| May 11, 2023 | 7 | STIPULATION and Proposed Order - filed by AbbVie Inc.. (Tigan, Jeremy) Modified on 5/11/2023 (nms). (Entered: 05/11/2023) (2) |
| May 4, 2023 | 6 | MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin - filed by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/04/2023) (9) |
| Apr 24, 2023 | 1 | Complaint* (1) |
| Apr 24, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 04/24/2023) (3) |
| Apr 24, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 13, 2023. Date of Expiration of Patent: July 23, 2039. (mkr) (Entered: 04/24/2023) (2) |
| Apr 24, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (mkr) (Entered: 04/24/2023) (1) |
| Apr 24, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (mkr) (Entered: 04/24/2023) (1) |
